CA3229469A1 - Plate-forme de dosage de transglutaminase in vitro basee sur une puce a proteines pour cartographie d'epitopes et conception d'immunogene - Google Patents

Plate-forme de dosage de transglutaminase in vitro basee sur une puce a proteines pour cartographie d'epitopes et conception d'immunogene Download PDF

Info

Publication number
CA3229469A1
CA3229469A1 CA3229469A CA3229469A CA3229469A1 CA 3229469 A1 CA3229469 A1 CA 3229469A1 CA 3229469 A CA3229469 A CA 3229469A CA 3229469 A CA3229469 A CA 3229469A CA 3229469 A1 CA3229469 A1 CA 3229469A1
Authority
CA
Canada
Prior art keywords
transglutaminase
glutamine
peptide
motifs
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3229469A
Other languages
English (en)
Inventor
Chen Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3229469A1 publication Critical patent/CA3229469A1/fr
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/52—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving transaminase
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention concerne des méthodes pour la détermination et la manipulation d'épitopes immunodominants par l'intermédiaire respectivement d'une cartographie et d'une optimisation des motifs de modification de transglutaminase contenant de la glutamine. L'invention révèle que les motifs de modification de transglutaminase contenant de la glutamine donneurs d'acyle d'un peptide composent les séquences d'épitopes immunodominants reconnues par l'immunité et correspondent à celles-ci, et la réactivité de la transglutaminase des motifs est en corrélation positive avec leur immunogénicité. L'invention concerne en outre une approche pour la conception d'un immunogène, l'immunogénicité d'une protéine pouvant être manipulée par des mesures de génie protéique modifiant la réactivité de la transglutaminase comme la substitution/mutation, délétion, ou insertion d'acides aminés, l'introduction directe/la création de résidus/motifs de glutamine, ou toute combinaison de ceux-ci.
CA3229469A 2021-08-20 2022-08-19 Plate-forme de dosage de transglutaminase in vitro basee sur une puce a proteines pour cartographie d'epitopes et conception d'immunogene Pending CA3229469A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163235135P 2021-08-20 2021-08-20
US63/235,135 2021-08-20
PCT/IB2022/000547 WO2023021335A2 (fr) 2021-08-20 2022-08-19 Plate-forme de dosage de transglutaminase in vitro basée sur une puce à protéines pour cartographie d'épitopes et conception d'immunogène

Publications (1)

Publication Number Publication Date
CA3229469A1 true CA3229469A1 (fr) 2023-02-23

Family

ID=85240106

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3229469A Pending CA3229469A1 (fr) 2021-08-20 2022-08-19 Plate-forme de dosage de transglutaminase in vitro basee sur une puce a proteines pour cartographie d'epitopes et conception d'immunogene

Country Status (3)

Country Link
AU (1) AU2022329479A1 (fr)
CA (1) CA3229469A1 (fr)
WO (1) WO2023021335A2 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060032140A (ko) * 2003-05-30 2006-04-14 센토코 인코포레이티드 트랜스글루타미나아제를 이용한 신규 에리트로포이에틴접합체의 형성

Also Published As

Publication number Publication date
WO2023021335A2 (fr) 2023-02-23
WO2023021335A3 (fr) 2023-06-01
WO2023021335A4 (fr) 2023-07-20
AU2022329479A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
Reineke et al. Applications of peptide arrays prepared by the SPOT-technology
Basak et al. Comprehensive characterization of glycosylation and hydroxylation of basement membrane collagen IV by high-resolution mass spectrometry
Esposito et al. Mammalian transglutaminases: identification of substrates as a key to physiological function and physiopathological relevance
Erales et al. Ubiquitin-independent proteasomal degradation
Im et al. Transglutaminase II: a new class of GTP-binding protein with new biological functions
Elli et al. Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver
Wang et al. Rapid analysis of protein farnesyltransferase substrate specificity using peptide libraries and isoprenoid diphosphate analogues
MORGAN et al. PKC‐dependent signalling mechanisms in differentiated smooth muscle
Sugimura et al. Identification of preferred substrate sequences for transglutaminase 1–development of a novel peptide that can efficiently detect cross‐linking enzyme activity in the skin
Knight et al. Profiling the kinome: current capabilities and future challenges
Qin et al. Recent advances in genetic code expansion techniques for protein phosphorylation studies
Hougland et al. Context-dependent substrate recognition by protein farnesyltransferase
Proctor et al. Selection and optimization of enzyme reporters for chemical cytometry
Pham et al. Peeling away the layers of ubiquitin signaling complexities with synthetic ubiquitin–protein conjugates
US9051595B2 (en) Malt1 specific cleavage in assay and screening method
US20250067753A1 (en) Protein array-based in vitro transglutaminase assay platform for epitope mapping and immunogen design
CA3229469A1 (fr) Plate-forme de dosage de transglutaminase in vitro basee sur une puce a proteines pour cartographie d'epitopes et conception d'immunogene
Demény et al. Structure of transglutaminases: unique features serve diverse functions
Song et al. Stability of thioester intermediates in ubiquitin‐like modifications
Pardin et al. Photolabeling of tissue transglutaminase reveals the binding mode of potent cinnamoyl inhibitors
Liu A protein microarray-based in vitro transglutaminase assay platform for epitope mapping and immunogen design: implication for transglutaminase-mediated immunodominant determination
Textoris-Taube et al. The N-terminal flanking region of the TRP2360–368 melanoma antigen determines proteasome activator PA28 requirement for epitope liberation
Liu A protein microarray-based in vitro transglutaminase assay platform for epitope mapping and peptide discovery: implication for transglutaminase-mediated immunodominant determination
JP5082094B2 (ja) トランスグルタミナーゼ基質反応性を有するペプチド及びその利用
Liu A protein microarray-based in vitro transglutaminase assay platform for epitope mapping and peptide discovery

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240219

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241122

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - SMALL

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250805

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250805

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250805

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251210

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL

Year of fee payment: 3

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - SMALL

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260204

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260204